89 related articles for article (PubMed ID: 16487170)
1. FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma.
Kumar S; Raje N; Hideshima T; Ishitsuka K; Podar K; Le Gouille S; Chauhan D; Richardson P; Munshi NC; Anderson K
Br J Haematol; 2006 Mar; 132(6):698-704. PubMed ID: 16487170
[TBL] [Abstract][Full Text] [Related]
2. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
3. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
6. Requirement of soluble factors produced by bone marrow stromal cells on the growth of novel established human myeloma cell line.
Aikawa S; Hatta Y; Tanaka M; Kaneita Y; Yasukawa K; Sawada U; Horie T; Tsuboi I; Aizawa S
Int J Oncol; 2003 Mar; 22(3):631-7. PubMed ID: 12579318
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Hideshima T; Catley L; Raje N; Chauhan D; Podar K; Mitsiades C; Tai YT; Vallet S; Kiziltepe T; Ocio E; Ikeda H; Okawa Y; Hideshima H; Munshi NC; Yasui H; Richardson PG; Anderson KC
Br J Haematol; 2007 Sep; 138(6):783-91. PubMed ID: 17760810
[TBL] [Abstract][Full Text] [Related]
8. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson KC
Oncogene; 2007 Apr; 26(16):2374-80. PubMed ID: 17016430
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
Neri P; Yasui H; Hideshima T; Tassone P; Raje N; Catley LP; Ishitsuka K; Blotta S; Kiziltepe T; Ocio EM; Fulciniti M; Kanekal S; Elliott GT; Munshi NC; Anderson KC
Br J Haematol; 2006 Jul; 134(1):37-44. PubMed ID: 16803565
[TBL] [Abstract][Full Text] [Related]
11. Antimyeloma effects of a sesquiterpene lactone parthenolide.
Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H
Clin Cancer Res; 2008 Mar; 14(6):1814-22. PubMed ID: 18347184
[TBL] [Abstract][Full Text] [Related]
12. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Mitsiades CS; Ocio EM; Pandiella A; Maiso P; Gajate C; Garayoa M; Vilanova D; Montero JC; Mitsiades N; McMullan CJ; Munshi NC; Hideshima T; Chauhan D; Aviles P; Otero G; Faircloth G; Mateos MV; Richardson PG; Mollinedo F; San-Miguel JF; Anderson KC
Cancer Res; 2008 Jul; 68(13):5216-25. PubMed ID: 18593922
[TBL] [Abstract][Full Text] [Related]
13. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
14. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
[TBL] [Abstract][Full Text] [Related]
15. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
16. Drug insight: thalidomide as a treatment for multiple myeloma.
Kumar S; Anderson KC
Nat Clin Pract Oncol; 2005 May; 2(5):262-70. PubMed ID: 16264962
[TBL] [Abstract][Full Text] [Related]
17. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
[TBL] [Abstract][Full Text] [Related]
18. Advances in the biology of multiple myeloma: therapeutic applications.
Anderson K
Semin Oncol; 1999 Oct; 26(5 Suppl 13):10-22. PubMed ID: 10528890
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antimyeloma effects of zoledronate and simvastatin.
Schmidmaier R; Simsek M; Baumann P; Emmerich B; Meinhardt G
Anticancer Drugs; 2006 Jul; 17(6):621-9. PubMed ID: 16917207
[TBL] [Abstract][Full Text] [Related]
20. Auger electron emitter against multiple myeloma--targeted endo-radio-therapy with 125I-labeled thymidine analogue 5-iodo-4'-thio-2'-deoxyuridine.
Morgenroth A; Dinger C; Zlatopolskiy BD; Al-Momani E; Glatting G; Mottaghy FM; Reske SN
Nucl Med Biol; 2011 Oct; 38(7):1067-77. PubMed ID: 21982576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
